Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466673 | 0.79 | IDO1 (0.42) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL7574131 | 0.79 | MAOA (0.44) | MAPTBRPF1CREBBPL3MBTL1ALDH1A1 | |
| SCHEMBL31728760 | 0.72 | IDO1 (0.55) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL1462143 | 0.72 | IDO1 (0.55) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL9899738 | 0.71 | IDO1 (0.53) | IDO1MAPTGSK3BBRPF1CREBBP | |
| Sulfuric Acid SCHEMBL29636505 | 0.70 | IDO1 (0.45) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL7852811 | 0.70 | IDO1 (0.49) | IDO1MAPTGSK3BTDO2ALDH1A1 | |
| SCHEMBL11462474 | 0.70 | IDO1 (0.52) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL87439 | 0.68 | IDO1 (0.50) | IDO1MAPTGSK3BBRPF1CREBBP | |
| SCHEMBL2767246 | 0.68 | IDO1 (0.50) | IDO1MAPTGSK3BBRPF1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | IDO1 1964/4885MAPT 734/4885GSK3B 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.